At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD
In Brief
A Phase 2 clinical trial evaluating Cyclophosphamide, Bortezomib, and 2 other interventions for Multiple Myeloma. Completed, enrolled 163 participants across 42 sites in 10 countries.
Detailed Summary
The purpose of this study is to test the effectiveness and safety of adding cyclophosphamide or lenalidomide to the VD combination in the treatment of patients with multiple myeloma that have achieved a stable response after 4 initial cycles of treatment with VD. Multiple myeloma is the second most common cancer of the blood. Bortezomib disrupts the life cycle of the cell, affecting numerous biologic pathways, including those related to growth and survival of cancer cells.
Study Details
Timeline
Interventions
500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
10 mg orally daily, days 1-14 for cycles 5 to 8